Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) COO Patrick John Finn sold 229 shares of the firm's stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $45.59, for a total value of $10,440.11. Following the completion of the transaction, the chief operating officer now owns 274,466 shares in the company, valued at $12,512,904.94. The trade was a 0.08 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Patrick John Finn also recently made the following trade(s):
- On Monday, November 11th, Patrick John Finn sold 10,340 shares of Twist Bioscience stock. The stock was sold at an average price of $48.00, for a total transaction of $496,320.00.
- On Wednesday, November 6th, Patrick John Finn sold 6,239 shares of Twist Bioscience stock. The stock was sold at an average price of $44.60, for a total transaction of $278,259.40.
- On Monday, November 4th, Patrick John Finn sold 2,681 shares of Twist Bioscience stock. The shares were sold at an average price of $41.56, for a total transaction of $111,422.36.
- On Wednesday, October 23rd, Patrick John Finn sold 2,261 shares of Twist Bioscience stock. The stock was sold at an average price of $43.09, for a total value of $97,426.49.
Twist Bioscience Price Performance
Collect $7k per month from Tesla’s SECRET dividend
From Investors Alley | Ad
Tesla doesn't pay a traditional dividend....
But I just discovered a secret backdoor to collect a secret 69% dividend from Tesla…
Which could put up to $7,013 in your pocket every month…
Click here to discover the new #1 way to invest in Tesla
TWST opened at $45.62 on Wednesday. The company's 50 day moving average price is $46.22 and its two-hundred day moving average price is $46.48. The firm has a market capitalization of $2.71 billion, a price-to-earnings ratio of -12.67 and a beta of 1.85. Twist Bioscience Co. has a fifty-two week low of $27.41 and a fifty-two week high of $60.90.
Institutional Trading of Twist Bioscience
Several institutional investors have recently modified their holdings of TWST. Principal Financial Group Inc. lifted its holdings in Twist Bioscience by 210.2% during the 2nd quarter. Principal Financial Group Inc. now owns 122,911 shares of the company's stock worth $6,057,000 after buying an additional 83,287 shares during the period. Victory Capital Management Inc. boosted its holdings in Twist Bioscience by 4,133.1% in the second quarter. Victory Capital Management Inc. now owns 308,171 shares of the company's stock valued at $15,187,000 after acquiring an additional 300,891 shares during the last quarter. Arizona State Retirement System increased its position in Twist Bioscience by 1.9% during the 2nd quarter. Arizona State Retirement System now owns 16,187 shares of the company's stock valued at $798,000 after purchasing an additional 308 shares during the period. Los Angeles Capital Management LLC raised its holdings in Twist Bioscience by 16.7% during the 2nd quarter. Los Angeles Capital Management LLC now owns 10,304 shares of the company's stock worth $508,000 after purchasing an additional 1,475 shares during the last quarter. Finally, Strategic Financial Concepts LLC acquired a new position in shares of Twist Bioscience in the 2nd quarter worth approximately $556,000.
Analysts Set New Price Targets
A number of equities analysts have recently commented on TWST shares. Evercore ISI boosted their price target on Twist Bioscience from $52.00 to $56.00 and gave the stock an "outperform" rating in a report on Tuesday, October 1st. Robert W. Baird increased their target price on shares of Twist Bioscience from $46.00 to $48.00 and gave the stock an "outperform" rating in a report on Tuesday, November 19th. Scotiabank raised their price target on shares of Twist Bioscience from $50.00 to $54.00 and gave the company a "sector outperform" rating in a research note on Tuesday, November 19th. Wolfe Research started coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They set an "outperform" rating and a $60.00 price objective for the company. Finally, Leerink Partners raised their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a "market perform" rating in a research report on Thursday, October 17th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, Twist Bioscience presently has an average rating of "Moderate Buy" and a consensus price target of $51.90.
View Our Latest Stock Report on Twist Bioscience
Twist Bioscience Company Profile
(
Get Free Report)
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
